JOURNEY MEDICAL CORP (DERM) Stock Price, Quote, News and Overview
NASDAQ:DERM - Nasdaq - US48115J1097 - Common Stock - Currency: USD
DERM Quote, Performance and Key Statistics
7
+0.18 (+2.64%)
The current stock price of DERM is 7 USD. In the past month the price decreased by -6.29%. In the past year, price increased by 94.44%.
DERM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.87 | 676.41B | ||
| JNJ | JOHNSON & JOHNSON | 15.22 | 367.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.24 | 299.26B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.93 | 218.30B | ||
| MRK | MERCK & CO. INC. | 9.96 | 194.81B | ||
| PFE | PFIZER INC | 7.26 | 132.58B | ||
| SNY | SANOFI-ADR | 13.57 | 126.50B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.34B | ||
| GSK | GSK PLC-SPON ADR | 7.02 | 78.45B | ||
| ZTS | ZOETIS INC | 27.01 | 72.38B | ||
| HLN | HALEON PLC-ADR | 22.73 | 50.17B |
Related stock screener links
About DERM
Company Profile
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Company Info
JOURNEY MEDICAL CORP
9237 E Via De Ventura Blvd., Suite 105, Suite 105
Scottsdale ARIZONA 94025 US
CEO: Thomas G. Wiggans
Employees: 41
Phone: 14804346670
JOURNEY MEDICAL CORP / DERM FAQ
What is the stock price of JOURNEY MEDICAL CORP today?
The current stock price of DERM is 7 USD. The price increased by 2.64% in the last trading session.
What is the ticker symbol for JOURNEY MEDICAL CORP stock?
The exchange symbol of JOURNEY MEDICAL CORP is DERM and it is listed on the Nasdaq exchange.
On which exchange is DERM stock listed?
DERM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JOURNEY MEDICAL CORP stock?
10 analysts have analysed DERM and the average price target is 10.07 USD. This implies a price increase of 43.89% is expected in the next year compared to the current price of 7. Check the JOURNEY MEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JOURNEY MEDICAL CORP worth?
JOURNEY MEDICAL CORP (DERM) has a market capitalization of 121.10M USD. This makes DERM a Micro Cap stock.
How many employees does JOURNEY MEDICAL CORP have?
JOURNEY MEDICAL CORP (DERM) currently has 41 employees.
What are the support and resistance levels for JOURNEY MEDICAL CORP (DERM) stock?
JOURNEY MEDICAL CORP (DERM) has a support level at 6.17 and a resistance level at 7.44. Check the full technical report for a detailed analysis of DERM support and resistance levels.
Is JOURNEY MEDICAL CORP (DERM) expected to grow?
The Revenue of JOURNEY MEDICAL CORP (DERM) is expected to grow by 25.96% in the next year. Check the estimates tab for more information on the DERM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy JOURNEY MEDICAL CORP (DERM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DERM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DERM, evaluating the profitability, health, valuation and growth aspects
- JOURNEY MEDICAL CORP (DERM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JOURNEY MEDICAL CORP (DERM) Sales and EPS estimates to see what analysts future expectations are.
- JOURNEY MEDICAL CORP (DERM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JOURNEY MEDICAL CORP (DERM) Insider and Institutional Ownership to learn about the owners and their transactions.
- JOURNEY MEDICAL CORP (DERM) Stock Chart to make your own analysis
- JOURNEY MEDICAL CORP (DERM) Latest news and press-releases to stay up to date.
Does JOURNEY MEDICAL CORP (DERM) stock pay dividends?
DERM does not pay a dividend.
When does JOURNEY MEDICAL CORP (DERM) report earnings?
JOURNEY MEDICAL CORP (DERM) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of JOURNEY MEDICAL CORP (DERM)?
JOURNEY MEDICAL CORP (DERM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
What is the Short Interest ratio of JOURNEY MEDICAL CORP (DERM) stock?
The outstanding short interest for JOURNEY MEDICAL CORP (DERM) is 2.77% of its float. Check the ownership tab for more information on the DERM short interest.
DERM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DERM. When comparing the yearly performance of all stocks, DERM is one of the better performing stocks in the market, outperforming 96.93% of all stocks.
DERM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DERM. DERM has a bad profitability rating. Also its financial health evaluation is rather negative.
DERM Financial Highlights
Over the last trailing twelve months DERM reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -378.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.28% | ||
| ROE | -73.11% | ||
| Debt/Equity | 1.24 |
DERM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to DERM. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 72.5% and a revenue growth 25.96% for DERM